About this trial
This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy.
Patient Profile
Advanced human epidermal growth factor 2 (HER2)-positive stomach and esophageal cancers that are no longer treatable with surgery (unresectable) or chemoradiation, and/or have grown or spread to other parts of the body (metastatic)
Where’s this trial being run?
St James’s Hospital
Can I join this study / trial?
The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.
It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.
For more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | HERIZON-GEA-01 (ZWI-ZW25-301) Zymeworks |
|---|---|
| Number: | 21-35 |
| Full Title: | HERIZON-GEA-01 (ZWI-ZW25-301) Zymeworks: A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA) |
| Principal Investigator: | Professor Maeve Lowery |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | Zymeworks Inc |
| Recruitment Started: |
Global: Ireland: |
| Global Recruitment Target: | 714 |
|---|---|
| Ireland Recruitment Target: | 6 (competitive) |